Neoleukin Therapeutics CEO Donna Cochener (L) and Neurogene CEO Rachel McMinn
July 18, 2023 10:18 AM EDTUpdated 03:01 PM
Startups
Deals
Cell/Gene Tx

New York gene ther­a­py start­up Neu­ro­gene eyes $200M from Ne­oleukin Nas­daq swap

Kyle LaHucik

Senior Reporter

Ne­oleukin Ther­a­peu­tics has found its re­verse merg­er part­ner about four months af­ter putting up the for-sale sign, as the Seat­tle biotech gives way to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times